HOME >> BIOLOGY >> NEWS
Study provides new details of 'the birth of a virus'

BOSTON - With sinister efficiency, retroviruses such as HIV use only a small portion of their genetic programming to steal away from the cell where they were born and infect other cells. A study published this week by scientists at Dana-Farber Cancer Institute provides new details of how retroviruses make their escape and cloak themselves in the cell's membrane to avoid attack from the body's immune system.

The study, published in the November 21 issue of the Proceedings of the National Academy of Sciences, is one of three in the journal to focus on the mechanics of viral departure from cells - research that may one day lead to new techniques for arresting the process and preventing the spread of viral infection within the body.

"The last stages of the formation of viruses within cells and the process by which viruses leave cells are among the least understood aspects of the viral life cycle," says senior author Heinrich Gttlinger, M.D., of Dana-Farber and Harvard Medical School. "Our research sheds light on previously unknown aspects of this process and on the mechanisms that cause a virus to assemble in the first place."

The Dana-Farber study spotlights the function of ubiquitins, which help viruses break free from the cells where they were born, and on a viral segment known as the "late domain," which is in a protein called Gag. The domain, as its name suggests, comes into play late in the process by which viruses are assembled inside cells, just before they leave to infect other cells.

The process works like this: After infecting a cell, a virus takes over a cell's reproductive machinery to produce thousands of copies of itself. The not-yet-fully-assembled viruses - really just packets of RNA at this point - congregate inside the cell membrane like protesters pressing against a police barricade. The cell membrane begins to bulge and eventually forms a "bubble" that seals the viral RNA off from the rest of th
'"/>

Contact: Todd Ringler
todd_ringler@dfci.harvard.edu
617-632-5357
Dana-Farber Cancer Institute
20-Nov-2000


Page: 1 2 3

Related biology news :

1. Study: Emission of smog ingredients from trees is increasing rapidly
2. Study explores gene transfer to modify underlying course of Alzheimers disease
3. Study reveals why eyes in some paintings seem to follow viewers
4. Study by Israeli scientists provides insight on DNA code
5. Study reveals first genetic step necessary for prostate cancer growth
6. Study of flu patients reveals virus outsmarting key drug
7. Study in Science reveals recreational fishing takes big bite of ocean catch
8. Study suggests cell-cycle triggers might be cancer drug targets
9. Study narrows search for genes placing men at increased risk for prostate cancer
10. Study links high carbohydrate diet to increased breast cancer risk
11. Study explains spatial orientation differences between sexes

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Study provides new details the birth virus

(Date:5/14/2015)... , May 14, 2015 Research and Markets ... of the "Fingerprint Sensors Market in Smart Mobile ... This report believes that 2014 was a watershed year ... Apple,s introduction of ,Apple Pay,. Apple gave fingerprint sensors ... mobile payment service. Fingerprint sensors are a must-have feature ...
(Date:5/11/2015)... DAYTON, Ohio , May 11, 2015  Through a ... Ohio had a strong showing at AUVSI,s ... . These representatives of Ohio,s UAS ... domestic and abroad from all points along the UAS ecosystem. ... Dayton Development Coalition,s (DDC) Vice President for Aerospace Rich ...
(Date:5/8/2015)... May 8, 2015 Synaptics Inc. (NASDAQ: SYNA ... that members of the executive management team will present at ... Technology, Media and Telecom Conference Date: May 18, 2015 ... Boston, MA Cowen and Company ... 2:45pm ET Location: The New York Palace Hotel, ...
Breaking Biology News(10 mins):Global Smart Mobile Devices Fingerprint Sensors Market 2015-2019: Key Vendors are Authentec, Validity Sensors, Fingerprint Cards, Next Biometrics Group. IDEX, and Qualcomm 2Ohio Flies High at Unmanned '15, Sets Stage for Ohio UAS Conference 2Synaptics to Present at Upcoming Investor Conferences 2
(Date:5/21/2015)... 2015 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or the ... develops and commercializes proprietary technologies and products for advanced ... for the second fiscal quarter ended March 31, 2015. ... to advance business with our existing customers and to ... and CEO of SQI. "The delivery of a fully ...
(Date:5/21/2015)... San Francisco, CA (PRWEB) May 21, 2015 ... microbiome sequencing, has announced a partnership with PicnicHealth, ... records for patients. Participants diagnosed with Inflammatory Bowel ... as well as a complementary uBiome research kit. ... Summer 2014. , For more ...
(Date:5/21/2015)... LOS ANGELES , May 21, 2015 /PRNewswire/ ... research and development company specializing in oncology, today ... 2 clinical trial with aldoxorubicin for the treatment ... of brain cancer.  The open-label, multisite trial is ... of aldoxorubicin in patients whose tumors have progressed ...
(Date:5/21/2015)... 2015 Tunnell Consulting, Inc. ... as senior statistician and Principal, a position to which ... the management and analysis of complex and large data ... , “We’re delighted to have Julia join the Tunnell ... said Dr. Philippe Cini, Group Vice President and leader ...
Breaking Biology Technology:SQI Diagnostics Reports Second Quarter Financial Results 2SQI Diagnostics Reports Second Quarter Financial Results 3SQI Diagnostics Reports Second Quarter Financial Results 4SQI Diagnostics Reports Second Quarter Financial Results 5SQI Diagnostics Reports Second Quarter Financial Results 6SQI Diagnostics Reports Second Quarter Financial Results 7SQI Diagnostics Reports Second Quarter Financial Results 8uBiome Partners with PicnicHealth 2uBiome Partners with PicnicHealth 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7Julia O’Neill Joins Tunnell Consulting’s Operational and Process Improvement Practice 2
Cached News: